Restricted accessResearch articleFirst published online 2023-05
Clinical Experience of Cytologically Indeterminate Thyroid Nodules Designated as Negative on Molecular Testing Using ThyroSeq V3: A Retrospective Cohort Study
BongiovanniM, SpitaleA, FaquinWC, et al.The Bethesda system for reporting thyroid cytopathology: A meta-analysis. Acta Cytol, 2012; 56(4):333–339; doi: 10.1159/000339959
2.
HaugenBR, AlexanderEK, BibleKC, et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid, 2016; 26(1):1–133; doi: 10.1089/thy.2015.0020
3.
ChenT, GilfixBM, RiveraJ, et al.The role of the ThyroSeq v3 molecular test in the surgical management of thyroid nodules in the Canadian public health care setting. Thyroid, 2020; 30(9):1280–1287; doi: 10.1089/thy.2019.0539
4.
StewardDL, CartySE, SippelRS, et al.Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: A prospective blinded multicenter study. JAMA Oncol, 2019; 5(2):204–212; doi: 10.1001/jamaoncol.2018.4616
5.
JugR, FooWC, JonesC, et al.High-risk and intermediate-high–risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: Independent performance assessment at an academic institution. Cancer Cytopathol, 2020; 128(8):563–569; doi: 10.1002/cncy.22283
6.
DesaiD, LepeM, BalochZW, et al.ThyroSeq v3 for Bethesda III and IV: An institutional experience. Cancer Cytopathol, 2021; 129(2):164–170; doi: 10.1002/cncy.22362
7.
CartySE, OhoriNP, HilkoDA, et al.The clinical utility of molecular testing in the management of thyroid follicular neoplasms (Bethesda IV nodules). Ann Surg, 2020; 272(4):621–627; doi: 10.1097/SLA.0000000000004130
8.
LivhitsMJ, ZhuCY, KuoEJ, et al.Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: A randomized clinical trial. JAMA Oncol, 2021; 7(1):70–77; doi: 10.1001/jamaoncol.2020.5935
9.
ZhuCY, DonangeloI, GuptaD, et al.Outcomes of indeterminate thyroid nodules managed nonoperatively after molecular testing. J Clin Endocrinol Metab, 2021; 106(3):E1240–E1247; doi: 10.1210/clinem/dgaa887
10.
HuC, JingW, ChangQ, et al.Risk stratification of indeterminate thyroid nodules by novel multigene testing: A study of Asians with a high risk of malignancy. Mol Oncol, 2022; 16(8):1680–1693; doi: 10.1002/1878-0261.13205
